Prophylactic Eculizumab Use in Kidney Transplantation: A Review of the Literature and Report of a Case with Atypical Hemolytic Uremic Syndrome

Kasapoglu, Umut; Ruhi, CAGLAR; Tugcu, Murat; Boynuegri, Basak; Titiz, Izzet; Hancer, Veysel; Apaydin, Suheyla

doi:10.12659/aot.894665

Prophylactic Eculizumab Use in Kidney Transplantation: A Review of the Literature and Report of a Case with Atypical Hemolytic Uremic Syndrome

Kasapoglu U., Ruhi C., Tugcu M., Boynuegri B., Titiz I., Hancer V. S., ...Daha Fazla

ANNALS OF TRANSPLANTATION, cilt.20, 2015 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 20
Basım Tarihi: 2015
Doi Numarası: 10.12659/aot.894665
Dergi Adı: ANNALS OF TRANSPLANTATION
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Background: Atypical hemolytic uremic syndrome (aHUS) is a very rare disease, which presents with microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Progression to end-stage renal disease (ESRD) from acute kidney injury is observed in 60% of aHUS cases. The prognosis of aHUS patients who undergo kidney transplantation (Ktx) is generally poor, but these patients should be treated prophylactically with eculizumab to prevent recurrence after transplantation.